Axogen (Nasdaq:AXGN) today announced it has launched its Avive+ Soft Tissue Matrix.
Avive+ is intended to be used as a soft tissue barrier. It is a resorbable and multi-layer amniotic membrane allograft that provides temporary protection and tissue separation during peripheral nerve healing.
“Product innovation is integral to our mission at Axogen,” CEO and President Karen Zaderej said in a news release. “With the introduction of Avive+ Soft Tissue Matrix, we are excited to enhance our comprehensive solutions for nerve protection and address a significant need for patients with compression or non-transected nerve injuries.”
According to Axogen, nerve protection accounts for approximately $800 million of the overall nerve repair market. It covers a wide range of injuries and defects, including carpal and cubital tunnel syndromes, crush injuries and other non-transected traumatic nerve injuries. The company announced the first surgical implant of Avive+ in April of this year.
“As a hand surgeon, I’ve seen the positive impact of using Avive+ Soft Tissue Matrix,” said Dr. Sunishka Wimalawansa, associate professor of orthopedic and plastic surgery at Wright State University in Dayton, Ohio. “The multi-layer design provides ideal handling, a robust barrier that retains the inherent properties of an amniotic membrane, and most importantly, the opportunity to improve patient outcomes after acute traumatic injury.”
